Skip to main content

Table 1 Baseline characteristics of patients with pancreatic cancer

From: Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer

Variable All patients (n = 61)
Median age 64 (41–81)
Sex
 Male 35 (57%)
 Female 26 (43%)
Median tumor size (mm) 37 (11–100)
Median CA 19-9 levels 385.5 (5–102041)
CA 19-9
 < 37U/mL 13 (21%)
 ≥ 37U/mL 47 (77%)
 Missing data 1 (2%)
Tumor location
 Pancreas head 34 (56%)
 Pancreas body 4 (7%)
 Pancreas tail 13 (21%)
 Multiple 10 (16%)
T-stage
 T2 11 (18%)
 T3 15 (25%)
 T4 25 (41%)
 TX 2 (3%)
 Missing data 8 (13%)
Clinical stage
 Stage III 6 (10%)
 Stage IV 55 (90%)
Metastatic location
 Liver 25 (41%)
 Lung 4 (7%)
 Multiple 16 (26%)
 Other 6 (10%)
 Missing data 10 (16%)
N-stage
 N0 14 (23%)
 N1 25 (41%)
 NX 21 (34%)
 Missing data 1 (2%)
ECOG status
 0 13 (21%)
 1 34 (56%)
 2 10 (16%)
 Missing data 4 (7%)
First-line treatment
 Gemcitabine 6 (10%)
 FOLFIRINOX 30 (49%)
 Nab-Paclitaxel + 25 (41%)
 Gemcitabine
Second-line treatment
 Yes 17 (28%)
 No 44 (72%)
Prior anti-cancer surgery
 Yes 9 (15%)
 No 51 (84%)
 Missing data 1 (2%)